CNS Pharmaceuticals宣布举办虚拟投资者KOL连线环节，讨论多形性胶质母细胞瘤（GBM）及主要候选产品TPI 287CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287

动脉网2025-06-24

Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar与脑肿瘤中心创始医生兼皮埃蒙特亚特兰大医院神经肿瘤科主任艾琳·邓巴博士进行的讨论HOUSTON, TX /...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2545238463?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-24 21:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2545238463","market":"us","top_or_hot":-1,"title":"CNS Pharmaceuticals宣布举办虚拟投资者KOL连线环节，讨论多形性胶质母细胞瘤（GBM）及主要候选产品TPI 287CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287","media":"动脉网","content":"<div>\n<p>Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar与脑肿瘤中心创始医生兼皮埃蒙特亚特兰大医院神经肿瘤科主任艾琳·邓巴博士进行的讨论HOUSTON, TX /...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212913978ce7db&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CNS Pharmaceuticals宣布举办虚拟投资者KOL连线环节，讨论多形性胶质母细胞瘤（GBM）及主要候选产品TPI 287CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCNS Pharmaceuticals宣布举办虚拟投资者KOL连线环节，讨论多形性胶质母细胞瘤（GBM）及主要候选产品TPI 287CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-24 21:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212913978ce7db&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar与脑肿瘤中心创始医生兼皮埃蒙特亚特兰大医院神经肿瘤科主任艾琳·邓巴博士进行的讨论HOUSTON, TX /...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212913978ce7db&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNS","symbol_name":"科恩-斯蒂尔斯金融","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212913978ce7db&s=b","article_id":"2545238463","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212913978ce7db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2545238463","pubTimestamp":1750771500,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"The Virtual Investor KOL Connect segment featuring CNS Pharma is now available虚拟投资者KOL Connect关于CNS Pharma的片段现已上线。About CNS Pharmaceuticals, Inc.关于CNS制药公司CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.CNS Pharmaceuticals是一家临床阶段的制药公司，正在开发一系列用于治疗原发性和转移性脑及中枢神经系统癌症的抗癌候选药物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CNS":"科恩-斯蒂尔斯金融","CNSP":"CNS Pharmaceuticals, Inc.","KOL":"Market Vectors-Coal ETF","BK4007":"制药","BK4135":"资产管理与托管银行"},"translate_title":"CNS Pharmaceuticals Announces Virtual Investor KOL Connection Session to Discuss Glioblastoma Multiforme (GBM) and Key Product Candidates TPI 287CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme GBM and Lead Product Candidate TPI 287","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOL":1,"CNS":1,"CNSP":0.9},"content_text":"Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar与脑肿瘤中心创始医生兼皮埃蒙特亚特兰大医院神经肿瘤科主任艾琳·邓巴博士进行的讨论HOUSTON, TX /休斯顿，德克萨斯州 /ACCESS NewswireACCESS 新闻专线/ June 24, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:/ 2025年6月24日 / CNS Pharmaceuticals, Inc.（纳斯达克：CNSP中国船舶集团有限公司) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the release of a）（“CNS”或“公司”），一家专注于开发针对脑部和中枢神经系统原发性和转移性癌症的新型治疗方法的生物制药公司，今天宣布发布一项Virtual Investor KOL Connect segment虚拟投资者KOL连接环节featuring包含Dr. Erin Dunbar欧文·邓巴博士, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, who specializes in the comprehensive care of brain and spine tumor patients who are battling both primary and metastatic tumors.，脑肿瘤中心的创始医生之一，同时也是皮埃蒙特亚特兰大医院神经肿瘤学主任，专门从事脑和脊柱肿瘤患者的综合治疗，这些患者正在与原发性和转移性肿瘤作斗争。As part of the segment, Dr. Dunbar discussed the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma's lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.作为该环节的一部分，邓巴博士讨论了多形性胶质母细胞瘤的患者旅程和当前的治疗前景，以及CNS Pharma的主要候选产品TPI 287及其作为GBM治疗的潜力和未来在转移性肿瘤中的适应症。The Virtual Investor KOL Connect segment featuring CNS Pharma is now available虚拟投资者KOL Connect关于CNS Pharma的片段现已上线。here这里.。About CNS Pharmaceuticals, Inc.关于CNS制药公司CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.CNS Pharmaceuticals是一家临床阶段的制药公司，正在开发一系列用于治疗原发性和转移性脑及中枢神经系统癌症的抗癌候选药物。The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain.公司的药物候选物TPI 287是一种紫杉烷类化合物，能够稳定微管并抑制细胞分裂，从而引发细胞凋亡和细胞死亡。初步的临床疗效数据显示，TPI 287具有穿越血脑屏障的潜力，可用于治疗中枢神经系统肿瘤。TPI 287已经在超过350名患者中进行了临床试验，作为单一疗法或与贝伐单抗联合使用，用于治疗多种疾病或病症，包括复发性胶质母细胞瘤、复发性神经母细胞瘤和髓母细胞瘤、晚期恶性肿瘤、进展性肿瘤疾病、晚期不可切除的胰腺癌、转移性黑色素瘤以及脑转移的乳腺癌。To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients..迄今为止，TPI 287在患者中表现出极佳的安全性和高耐受性。For more information, please visit欲了解更多信息，请访问www.CNSPharma.comwww.CNSPharma.com, and connect with the Company on，与公司建立联系XX,，FacebookFacebook, and，以及LinkedIn领英.。Forward-Looking Statements前瞻性声明Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects.本新闻稿中的某些陈述是1933年《证券法》第27A条、1934年《证券交易法》第21E条以及1995年《私人证券诉讼改革法案》所指的前瞻性陈述，这些陈述涉及风险和不确定性。这些陈述与未来事件、未来预期、计划和前景有关。Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.尽管CNS认为这些前瞻性陈述中反映的预期在作出时是合理的，但实际结果可能与这些前瞻性陈述明示或暗示的结果有重大差异。CNS已尝试通过术语来识别前瞻性陈述，包括“相信”、“估计”、“预期”、“计划”、“项目”、“意图”、“潜力”、“可能”、“可以”、“也许”、“将”、“应该”、“大约”或其他传达未来事件或结果不确定性的词语来识别这些前瞻性陈述。These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. 'Risk Factors' in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ('SEC') and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC.这些声明仅为预测，涉及已知和未知的风险、不确定性及其他因素，包括市场和其他状况，以及 CNS 最近向证券交易委员会（“SEC”）提交的 Form 10-K 中“风险因素”项下讨论的内容，并不时在其 Form 10-Q 文件及其向 SEC 提交的其他公开文件中更新。Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law..本新闻稿中包含的任何前瞻性声明仅截至其发布日期。CNS 没有义务更新本新闻稿中包含的任何前瞻性声明，以反映在其日期之后发生的事件或情况，或反映未预期事件的发生，除非法律要求。CONTACTS:联系人：Investor Relations Contact投资者关系联系JTC Team, LLCJTC团队有限公司Jenene Thomas珍妮·托马斯908.824.0775908.824.0775CNSP@jtcir.comCNSP@jtcir.comSOURCE: CNS Pharmaceuticals, Inc.来源：CNS Pharmaceuticals, Inc.View the original查看原文press release新闻稿on ACCESS Newswire在ACCESS新闻专线","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2545238463","isCrawlerRequest":true}